percentage of americans taking glp 1 what percent are on Big shift in U.S. health! A new Gallup Neil Floch MD on X:

1 patient was diagnosed with paracentral acute middle maculopathy , a condition affecting the central retina

Different research goals require different products

Eden does not manufacture or dispense medications but connects patients with licensed healthcare providers

Anti-coagulants manage abnormal clotting

The FDA distinguishes between compounded medications from licensed 503A pharmacies and mass-produced 503B facilitiesa critical distinction for product consistency and oversight

According to the data presented at the 2025 European Society for Medical Oncology (ESMO) Congress, JSKN003 demonstrated an objective response rate (ORR) of 68.8% and a mPFS of 11.04 months in 32 patients with HER2-positive advanced colorectal cancer, showing a clear therapeutic advantage over existing therapies